TH159052A - Anticancer fusion protein - Google Patents

Abstract

DC60 (11/07/56) fusion protein containing the domain (a) where fragments that act ((functional fragment) of the hTRAIL protein sequencing with fragments Mentions begin with an amino acid at a location not lower than hTRAIL95 or a homologous origin of a fragment at a function with a sequence identity. At least 70% and the domain (b) where the anti-peptide effect New blood vessels (anti-angiogenic effector peptide) where the domain (b) sequence sequence is captured at the C end or the N end of the protein fusion domain (a). They can be used for cancer therapy, fusion proteins that contain the domain (a) where the functional fragment of the protein sequence sequence. hTRAIL, where a fragment begins with an amine acid at a position not lower than hTRAIL95, or a homologous origin of the fragment at a function with a sequence of sequences. At least 70% of the same sequence identity (sequence identity) and romen (b) where the anti-peptide New selection (anti-angiogenic effector peptide) where the domain (b) sequence sequence is captured at the C end or the N end of the protein fusion domain (a). Can be used for the treatment of Dr. Kama fast, patent medicine

Claims (1)

: DC60 (11/07/56) fusion protein (fusion protein) containing the domain (a) where the functional fragment ((functional fragment) of the hTRAIL protein sequence, where there is A fragment starts with an amino acid at a location not lower than hTRAIL95 or a homologous origin of a fragment with a function having the same sequence identity ) At least 70% and the domain (b) where the anti-peptide effect New blood vessels (anti-angiogenic effector peptide) where the domain (b) sequencing sequence is captured at the C end or the N end of the protein fusion domain (a). They can be used for cancer therapy, fusion proteins that contain the domain (a) where the functional fragment of the protein sequence sequence. hTRAIL, where a fragment begins with an amine acid at a position not lower than hTRAIL95, or a homologous origin of the fragment at a function with a sequence of sequences. At least 70% of the same sequence identity (sequence identity) and romen (b) where the anti-peptide effect New selection (anti-angiogenic effector peptide) where the domain (b) sequencing sequence is captured at the C end or the N end of the protein fusion domain (a). It can be used for Dr. Kamarue treatment. Privilege (item one) which will appear on the advertisement page: edit 10/01/2017 1. Fusion proteins include: - Domain (a) containing functional fragment of soluble hTRAIL protein sequences (soluble hTRAIL protein). sequence) starting with & nbs Tag: drug patent